Business, energy, technology, markets and global industry news from Business News Today

antibody drug conjugates

PharmaDeviceNews antibody drug conjugates
Representative image of oncology researchers reviewing molecular data in a biotechnology lab, reflecting Johnson & Johnson’s Firefly Bio deal and the race to advance degrader antibody conjugates for hard-to-treat solid tumors.
Pharma & Biotech

Why Johnson & Johnson is paying $1bn for Firefly Bio’s cancer drug platform

Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.

Read More
Representative image of cervical cancer treatment planning as Zai Lab’s TIVDAK approval expands China’s options for recurrent or metastatic disease.
Pharma & Biotech

TIVDAK approval gives Zai Lab a sharper China oncology story, but execution risk remains

TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.

Read More
Representative image of a lung cancer treatment setting, as OptiTROP-Lung05 data put sacituzumab tirumotecan at the centre of the first-line NSCLC immunotherapy debate.
Pharma & Biotech

Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Read More
Representative image: Enhertu’s EU recommendation could expand HER2 targeted cancer treatment options for patients with previously treated metastatic solid tumors, highlighting the growing role of antibody drug conjugates and precision oncology in advanced cancer care.
Pharma & Biotech

Enhertu nears wider EU approval as HER2 testing moves deeper into solid tumor oncology

Find out how Enhertu’s EU recommendation could reshape HER2 targeted treatment for metastatic solid tumors.

Read More
Representative image: A cancer patient receives infusion-based oncology care in a modern clinic, reflecting Datroway’s FDA approval as a new first-line treatment option for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy.
Pharma & Biotech

AstraZeneca and Daiichi Sankyo deepen ADC ambitions with Datroway’s TNBC approval

Datroway challenges chemotherapy in first-line TNBC. AstraZeneca and Daiichi Sankyo now face the real test: adoption, safety and access.

Read More
Representative image: An oncologist reviews breast cancer imaging with a patient in a clinical setting, reflecting how AstraZeneca and Daiichi Sankyo’s ENHERTU approval could reshape treatment options for HER2-positive early breast cancer.
Pharma & Biotech

ENHERTU enters curative-intent breast cancer care as FDA widens AstraZeneca and Daiichi Sankyo label

ENHERTU is moving earlier in breast cancer care. The bigger question is whether efficacy gains can outweigh ADC safety scrutiny.

Read More
Representative image of antibody-drug conjugate cancer research, illustrating the next-generation ADC platform strategy highlighted by Whitehawk Therapeutics at AACR 2026.
Pharma & Biotech

Can Whitehawk Therapeutics turn preclinical ADC depth into a real oncology pipeline advantage?

Whitehawk Therapeutics unveiled AACR 2026 data for three ADCs. Read what it means for pipeline differentiation, risk, and investor sentiment.

Read More
Representative image of bispecific antibody drug conjugate research as NEOK Bio highlights NEOK001 and NEOK002 at AACR 2026, drawing attention to the next wave of solid tumor ADC development.
Pharma & Biotech

Can bispecific ADCs give NEOK Bio a more credible route into solid tumor drug development?

NEOK Bio unveiled AACR 2026 data for NEOK001 and NEOK002. Read how its bispecific ADC strategy could reshape solid tumor competition.

Read More
Pharma & Biotech

Whitehawk Therapeutics sharpens HWK-016 case as MUC16 emerges as a stronger ADC target in gynecologic cancers

Whitehawk Therapeutics says new MUC16 data support HWK-016 in gynecologic cancers. Read what this could change for ADC development.

Read More
Pharma & Biotech

Why ABION’s ABN202 may be aiming beyond TROP2 antibody-drug conjugate resistance

ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.

Read More